Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IQVIA Holdings | Milan | Healthcare | Biotechnology & Medical Research | €26.27B | 26x | -2.42 | €153.40 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.95B | 27.9x | 0.07 | €41.19 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.20B | -5.8x | 0.05 | €6.81 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Milan | Healthcare | Biotechnology & Medical Research | €1.05B | 5.8x | 0.04 | €4.67 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Philogen SpA | Milan | Healthcare | Biotechnology & Medical Research | €859.07M | 18.8x | 0.02 | €21.30 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.5% Upside | Upgrade to Pro+ | |
Ulisse Biomed Spa | Milan | Healthcare | Biotechnology & Medical Research | €21.74M | -3.4x | 0.4 | €0.89 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Arterra Bio | Milan | Healthcare | Biotechnology & Medical Research | €16.91M | 12.8x | 0.52 | €2.54 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |